The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 06, 2018

Filed:

Jan. 15, 2016
Applicant:

Caribou Biosciences, Inc., Berkeley, CA (US);

Inventors:

Stan Johan Jozef Brouns, Wageningen, NL;

John Van Der Oost, Renkum, NL;

Assignee:

Caribou Biosciences, Inc., Berkeley, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/22 (2006.01); C12N 15/66 (2006.01); C12N 15/62 (2006.01); C12N 15/74 (2006.01); C07K 14/245 (2006.01); C12N 15/70 (2006.01); A61K 48/00 (2006.01); C12N 9/16 (2006.01); C12N 15/81 (2006.01); C12N 15/82 (2006.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01); C07K 14/47 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 9/22 (2013.01); A61K 48/005 (2013.01); C07K 14/245 (2013.01); C07K 14/47 (2013.01); C12N 9/16 (2013.01); C12N 15/62 (2013.01); C12N 15/66 (2013.01); C12N 15/70 (2013.01); C12N 15/74 (2013.01); C12N 15/81 (2013.01); C12N 15/82 (2013.01); C12N 15/86 (2013.01); C12N 15/902 (2013.01); C12N 15/907 (2013.01); A61K 38/00 (2013.01); C07K 2319/09 (2013.01); C07K 2319/22 (2013.01); C07K 2319/60 (2013.01); C07K 2319/71 (2013.01); C07K 2319/80 (2013.01); C07K 2319/85 (2013.01); C12N 2310/20 (2017.05); C12Y 301/21004 (2013.01);
Abstract

A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualizing, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualization, transcriptional activation or repression. A pair of ribonucleotides fused to FokI dimers may be used to generate double-strand breakages in the DNA to facilitate these applications in a sequence-specific manner.


Find Patent Forward Citations

Loading…